| Name | Ximelagatran |
| Description | Ximelagatran (H 376-95), a direct thrombin inhibitor, can be taken orally and acts solely by inhibiting the actions of thrombin. Ximelagatran is converted to the active agent melagatran in vivo. |
| In vitro | Ximelagatran, an orally administered direct thrombin inhibitor, is currently being developed for both the prophylaxis and treatment of thromboembolism. Once ingested, it is rapidly absorbed and converted into its active metabolite, Melagatran, which acts as a reversible, active-site inhibitor targeting both free and clot-bound thrombin, showcasing stable and reproducible pharmacokinetic properties. Initial research indicates Ximelagatran's promising efficacy and safety profile in preventing venous thromboembolism following total knee or hip replacement surgeries[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.22 mM), Sonication is recommended.
DMSO : 55 mg/mL (116.14 mM), Sonication is recommended.
H2O : Insoluble
|
| Keywords | Ximelagatran | Thrombin | Inhibitor | inhibit |
| Inhibitors Related | Dabigatran Etexilate Mesylate | (S)-(+)-Ibuprofen | Edoxaban | AEBSF hydrochloride | Heparin sodium salt | Ozagrel | Avatrombopag | Dabigatran etexilate | Argatroban Monohydrate | Eltrombopag Olamine | Anisindione | p-Hydroxycinnamic acid |
| Related Compound Libraries | Bioactive Compound Library | Approved Drug Library | ReFRAME Related Library | Drug-induced Liver Injury (DILI) Compound Library | Toxic Compound Library | Protease Inhibitor Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Human Metabolite Library |
United States
